Ono Pharmaceutical Co Ltd (Ono Pharmaceutical) undertakes the production, purchase and sale of prescription pharmaceuticals and diagnostic reagents. It operates through a single reportable business segment namely, Pharmaceutical business that focuses on R&D, manufacturing, purchasing and sales.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D department focuses on developing new drugs. The company is focusing in major four theraupeutic areas such as oncology, immunology, neurology and specialties. A few of Ono Pharmaceutical’s pipeline products include Opdivo intravenous infusion/ nivolumab for indications of cancer; ONO-4482 in Phase II for treatment of Melanoma; ONO-4686 in Phase II; ONO-7119, ONO-7914 and ONO-7122 for treating solid tumor in Phase I; ONO-4578 in Phase -I for treatment of gastric cancer, colorectal cancer, pancreatic cancer and non-small cell lung cancer. It has research facilities in Edinburgh and Cambridge, and the UK. In FY2023, the company spent JPY95,344 million on its R&D activities which as a percentage of revenue stood at 21.3%.